Peptide rich firming creams revenue is forecast to rise from USD 1,563.2 million in 2026 to USD 3,121.2 million by 2036, reflecting a 12.6% CAGR over the period. Firming and lifting benefits are expected to remain the leading functional segment with a 38.4% share, while serums are projected to dominate product types, accounting for a 44.1% share.